Drug Trial Radar · NCT03624543
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Actual
Start
Feb 14, 2019
Primary completion
Nov 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team
- First posted
- Aug 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.
Conditions
- Breast Cancer
Interventions
CFI-400945Drug
32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response defined by RECIST 1.1Time frame: 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Odette Cancer Centre
Toronto, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.